EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY 4.0

Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study

Giorgio Tettamanti iD, Xiaochen Shu, Hanna Mogensen iD, Helena Kopp Kallner, Tiit Mathiesen iD, Maria Feychting iD

Neuro-Oncology · 2026

DOI: 10.1093/neuonc/noaf228 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Giorgio Tettamanti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (G.T., H.M., M.F.). Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, Contraceptive Agents, Hormonal, Contraceptives, Oral, Hormonal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Lundbeck foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Studies of hormonal contraceptives and the risk of meningioma has often relied on self-reported information, primarily focusing on oral contraceptives. Recently, an association between progestins and meningioma was suggested. We aimed to analyze the association between hormonal contraceptives and meningioma using data from Swedish national registries.

Methods

We used the Swedish Cancer Register to identify women born 1955-1995, diagnosed with meningioma at age ≥20 years, between 2007 and 2015 (N = 1055). Twenty controls per case were randomly selected from the Swedish population register, matched by birth year and county of residence. We retrieved information regarding prescriptions of hormonal contraceptives from the National Prescribed Drug Register. Adjusted conditional logistic regression models were used to evaluate the association between hormonal contraceptive use and meningioma occurrence.

Results

Women prescribed hormonal contraceptives ≥1 year before the index date had an odds ratio (OR) of meningioma of 1.76 (95% CI, 1.53-2.03). For contraceptives containing medroxyprogesterone the OR was 5.49 (95% CI, 4.51-6.67), while the association was weaker for other progesterone contraceptives (OR = 1.34, 95% CI, 1.09-1.65). No association was found for intrauterine devices, vaginal rings, and subdermal implants.

Conclusions

This large register-based case-control study show a strong association between injectable hormonal contraceptives containing medroxyprogesterone and meningioma risk. The results add to the growing body of evidence of an association between meningiomas and progestins in general and the strong, consistent associations suggest a causal role of injectable medroxyprogesterone in meningioma growth. Our results correspond to 2 additional cases of meningioma per 10 000 women exposed to medroxyprogesterone per year.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsContraceptive Agents, HormonalContraceptives, Oral, HormonalHumansFemaleCase-Control StudiesRegistriesSwedenAdultMiddle AgedRisk FactorsYoung AdultAgedFollow-Up StudiesPrognosis

Substanzen

Contraceptive Agents, HormonalContraceptives, Oral, Hormonal

Autor:innen und Institutionen

  • Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (G.T., H.M., M.F.).
  • Department of Epidemiology, School of Public Health, Suzhou Medical College of Soochow University, Suzhou, China (X.S.).
  • Department of Immunology, Uppsala University, Uppsala, Sweden (H.M.).
  • Department of Clinical Sciences, Karolinska Institutet, Stockholm, Sweden (H.K.K.).
  • Department of Obstetrics and Gynecology, Danderyds Hospital, Danderyd, Sweden (H.K.K.).
  • Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark (T.M.).

ORCID-Profile: Giorgio Tettamanti, Hanna Mogensen, Tiit Mathiesen, Maria Feychting

Förderung

  • Swedish Research Council
  • Lundbeck foundation

Zitieren

APA

Tettamanti, G., Shu, X., Mogensen, H., Kopp Kallner, H., Mathiesen, T., & Feychting, M. (2026). Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf228

Vancouver

Tettamanti G, Shu X, Mogensen H, Kopp Kallner H, Mathiesen T, Feychting M. Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study. Neuro-Oncology. 2026. doi:10.1093/neuonc/noaf228

BibTeX
@article{Tettamanti2026,
  author = {Tettamanti, Giorgio and Shu, Xiaochen and Mogensen, Hanna and Kopp Kallner, Helena and Mathiesen, Tiit and Feychting, Maria},
  title = {Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study},
  journal = {Neuro-Oncology},
  year = {2026},
  doi = {10.1093/neuonc/noaf228}
}
Kostenlos starten →